Cara Therapeutics (NASDAQ:CARA) commences a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in patients with atopic dermatitis (AD).
The study will enroll approx. 240 adult subjects with AD.
The primary efficacy endpoint is the change from baseline in the weekly mean of the daily 24-hour Itch Numeric Rating Scale (I-NRS) score at Week 12 of the treatment period.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.